| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.TRANSPROCEED.2017.03.093 |
| P698 | PubMed publication ID | 28736028 |
| P50 | author | Yuta Ohno | Q84515177 |
| P2093 | author name string | A Suzuki | |
| T Tsuchiya | |||
| Y Itoh | |||
| T Deguchi | |||
| M Fujitani | |||
| K Horie | |||
| M Soda | |||
| K Kanamori | |||
| K Kitaichi | |||
| S Yoshikuni | |||
| A Shibayama | |||
| R Michiuchi | |||
| P2860 | cites work | Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients | Q28538933 |
| Dosing equation for tacrolimus using genetic variants and clinical factors | Q35629782 | ||
| Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects | Q35987461 | ||
| Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference | Q37379749 | ||
| Clinical pharmacokinetics of tacrolimus | Q41096852 | ||
| MDR1 genotypes do not influence the absorption of a single oral dose of 600 mg valacyclovir in healthy Chinese Han ethnic males | Q41324351 | ||
| Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. | Q42754368 | ||
| Effect of different tacrolimus levels on early outcomes after kidney transplantation | Q43901985 | ||
| Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients | Q44066270 | ||
| Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients | Q44486217 | ||
| Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus | Q44579589 | ||
| Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. | Q44632277 | ||
| The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. | Q44899003 | ||
| The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients | Q44914011 | ||
| CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation | Q44958936 | ||
| Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients | Q45122563 | ||
| Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians | Q45281322 | ||
| Trough tacrolimus concentrations in the first week after kidney transplantation are related to acute rejection. | Q45983572 | ||
| Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients | Q46512720 | ||
| Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients | Q46576181 | ||
| Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation | Q46690564 | ||
| A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype. | Q46796371 | ||
| Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression | Q46906576 | ||
| Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. | Q52965959 | ||
| CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III). | Q53122247 | ||
| Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation | Q71700445 | ||
| MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects | Q77133730 | ||
| CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients | Q79456645 | ||
| Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements | Q80252228 | ||
| CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients | Q80316046 | ||
| Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation | Q83522225 | ||
| Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients | Q84255299 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple drug resistance | Q643839 |
| P304 | page(s) | 1492-1498 | |
| P577 | publication date | 2017-07-01 | |
| P1433 | published in | Transplantation Proceedings | Q7834825 |
| P1476 | title | Association Between Tacrolimus Pharmacokinetics and Cytochrome P450 3A5 and Multidrug Resistance Protein 1 Exon 21 Polymorphisms | |
| P478 | volume | 49 |
Search more.